De Novo Genome Assembly Market Growth Outlook From $2.28 Billion In 2026 To $3.96 Billion By 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
De Novo Genome Assembly Market Size, Value And Growth Trajectory Through 2030
The de novo genome assembly market has experienced significant expansion recently. It is projected to grow from $1.99 billion in 2025 to $2.28 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%. The historical growth in this market can be attributed to several factors including the increasing use of next-generation sequencing, the growth of academic research initiatives, the adoption of genome assembly software, a rising demand in clinical diagnostics, and the development of plant and microbial genomics projects.
The de novo genome assembly market size is projected to experience swift expansion over the coming years. Its valuation is anticipated to reach $3.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.8%. This projected growth can be ascribed to several factors, including the incorporation of AI into genome assembly processes, the proliferation of cloud-based bioinformatics platforms, an increasing need for rapid custom genome sequencing, the advancement of precision medicine applications, and heightened investment in evolutionary and environmental genomics. Key developments expected during this forecast period encompass automated genome assembly pipelines, sophisticated cloud-based data analysis, the integration of high-throughput sequencing, tailored bioinformatics services, and improvements in visualization and annotation capabilities.
Get A Free Sample Report With In-Depth Market Insights:
De Novo Genome Assembly Market Development Factors: What’s Supporting Demand?
The escalating demand for personalized medicine is anticipated to drive the expansion of the de novo genome assembly market moving forward. Personalized medicine refers to medical treatments and therapies specifically designed for individual patients, based on their unique genetic makeup, biomarkers, and particular disease characteristics. This demand is on the rise due to advancements in genomic technologies and molecular diagnostics, which enable treatments to be customized according to an individual’s genetic profile, thereby improving outcomes and reducing side effects. De novo genome assembly enhances personalized medicine by reconstructing an individual’s genome from scratch, allowing for the discovery of unique genetic variants and structural alterations that are vital for precision therapies, tailored drug selection, and early disease intervention. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022, comprising seven cancer drugs and three for other diseases and conditions. Thus, the increasing need for personalized medicine is a key factor propelling the growth of the de novo genome assembly market.
De Novo Genome Assembly Market Segmentation: How Does The Market Break Down By Category?
The de novo genome assembly market covered in this report is segmented –
1) By Component: Software, Services
2) By Organism Type: Human, Animal, Plant, Microbial, Metagenomic Or Mixed Samples
3) By Technology: Next-Generation Sequencing, Third-Generation Sequencing, Sanger Sequencing, Other Technologies
4) By Application: Clinical Diagnostics, Agricultural Genomics, Environmental Genomics, Evolutionary Biology, Other Applications
5) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Hospitals And Clinics, Other End-Users
Subsegments:
1) By Software: Sequence Alignment Software, Genome Assembly Software, Error Correction And Quality Control Software, Visualization And Annotation Software
2) By Services: Genome Sequencing Services, Data Analysis And Interpretation Services, Custom Genome Assembly Services, Consulting And Bioinformatics Support Services
De Novo Genome Assembly Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the de novo genome assembly market are concentrating on developing innovative solutions, such as high-throughput genome assembly platforms, to accelerate genome reconstruction and enhance accuracy for complex and diverse organisms. These advanced systems integrate long- and short-read sequencing data to rapidly reconstruct complete genomes with high precision, enabling researchers to generate contiguous assemblies more quickly and manage intricate or repetitive genomic regions more efficiently than traditional methods. For instance, in May 2024, Dovetail Genomics Inc., a US-based genomics technology company, introduced the AssemblyLINK Assay, a high-throughput genome assembly platform engineered to expedite genome assembly workflows and boost the accuracy of de novo assemblies. The AssemblyLINK Assay combines proprietary scaffolding technology with existing sequencing data to produce highly contiguous genome assemblies, simplifies data processing through streamlined computational pipelines, and supports a broad spectrum of organisms, ranging from plants and animals to microbial communities. Its distinctive characteristics include compatibility with multiple sequencing platforms, minimized manual intervention, and optimized performance for complex and large genomes, making it especially valuable for biodiversity research and conservation genomics.
De Novo Genome Assembly Market Key Participants And Competitive Landscape
Major companies operating in the de novo genome assembly market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Illumina Inc., QIAGEN N.V., Novogene Corporation, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Medgenome labs pvt. Ltd, DNASTAR Inc., Nucleome Informatics Pvt Ltd, Seven Bridges Genomics, DNAnexus Inc., Strand Life Sciences Pvt. Ltd., BaseClear B.V., Dovetail Genomics LLC, SoftGenetics LLC, CosmosID Inc., Microba Life Sciences Ltd., GenomeScan B.V., BGI Genomics Co. Ltd., Macrogen Inc., SeqMatic LLC, NeuGen Biologicals.
View The Full De Novo Genome Assembly Market Report:
De Novo Genome Assembly Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the de novo genome assembly market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the de novo genome assembly market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model